COX2 overexpression is a prognostic marker for Stage III breast cancer (Q38474547)

3 September 2017

0 references

COX2 overexpression is a prognostic marker for Stage III breast cancer (English)

1 reference

3 September 2017

1 reference

7

Dong-Young Noh

1 reference

3 September 2017

3

Wonshik Han

1 reference

3 September 2017

2

Hyeong-Gon Moon

1 reference

3 September 2017

Hee Sung Kim

1

1 reference

3 September 2017

Cha Kyung Yom

series ordinal

4

1 reference

3 September 2017

Woo Ho Kim

series ordinal

5

1 reference

3 September 2017

Jun Ho Kim

series ordinal

6

1 reference

3 September 2017

language of work or name

English

0 references

publication date

28 April 2011

1 reference

Breast Cancer Research and Treatment

3 September 2017

published in

1 reference

3 September 2017

volume

132

1 reference

3 September 2017

issue

1

1 reference

3 September 2017

page(s)

51-59

1 reference

Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

COX inhibitors and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Cyclooxygenase-2: a target for the prevention and treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Cox-2 expression on tissue microarray of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Genes that mediate breast cancer metastasis to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

COX-2 involvement in breast cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Cyclooxygenase 2: a molecular target for cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Homeostatic imbalance between apoptosis and cell renewal in the liver of premature aging Xpd mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

The role of cyclooxygenase-2 in breast cancer: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1521-3

10.1007/S10549-011-1521-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1016691772

0 references

1 reference